Tyligand Bioscience
was founded in 2018, located in Zhangjiang Medicine Valley in Shanghai Pilot Free Trade Zone
We have an integrated 45,000 ft2 state of the art facility that houses medicinal chemistry, biological testing, ADME assessment; process, formulation and clinical development teams to support the core IP generation research and preclinical development, IND applications, and early clinical development efforts.
Who we are
-
The team is dedicated to the discovery and development of innovative drugs for cancer and autoimmune diseases, leveraging deep knowledge of the signal transduction pathways of tumorigenesis, expertise in synthetic chemistry, and insight into the tumor microenvironment.
Our goal is to become an efficient drug innovation engine to create and sustain a pipeline of breakthrough medicines that are efficacious and accessible to patients worldwide.
Core Values
-
People
Respect for people is at the very core of our values. We are committed to providing a nourishing environment for employees to discover their passions, unleash their creativities and realize their full potentials.
Integrity
Integrity is the foundation for a scientific enterprise and the most basic requirement for Tyligand team members. We believe success will only come only if we insist on seeking the truth.
Innovation
Innovation is not only our core competency but also the reason for our being. We believe that every problem plaguing the humanity has a solution to be discovered or optimized. We strive to build a win-win platform for the open minded and the persistent scientists to connect, challenge each other, test hypotheses and co-create answers that matter.
Responsibility
We will always bear in mind the responsibilities that come with the power of science in our hands, and the commitments made to our families, coworkers, investors, partners, patients, the environment, and the society.
Tyligand Milestones
May 2018
Founded in 2018
Founders include seasoned pharma executives, experienced drug hunter with stellar track record, and leading international authority on protein phosphatase research
May 2018
Dec 2019
Seed Funding
Oriza Holdings, Med-Fine Capital, Bohe Angel and K2VC
Apr 2021
Series A Funding
VI Ventures, Yijing Investment and CMS (China Medical System)
Apr 2021
Mar 2022
TSN084 Clinical Trial
TSN084 achieved First Patient Dose in the US
Oct 2022
ADC Payload Design and Development
Collaborated with GeneQuantum and delivered novel payloads for ADC development
Oct 2022
Dec 2022
TSN222 IND FDA
TSN222 IND Clearance from US FDA
Feb 2023
TSN222 IND NMPA
TSN222 IND Clearance from China NMPA
Feb 2023
Jul 2023
Series A+ Funding
Jul 2023
TSN222 Clinical Trial
TSN222 Achieved First Patient Dose in China
Jul 2023